<DOC>
	<DOCNO>NCT01664533</DOCNO>
	<brief_summary>This prospective , multicenter observational study evaluate efficacy , safety , tolerability Tarceva ( erlotinib ) second-line treatment patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) progress pemetrexed-containing first-line chemotherapy . Eligible patient follow withdrawal consent , lost-to-follow-up , study termination , whichever occur first .</brief_summary>
	<brief_title>An Observational Study Erlotinib ( Tarceva ) Second-line Treatment Patients With Locally Advanced Metastatic Non-small Cell Lung Cancer After Failure Pemetrexed First-line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Adult patient â‰¥ 18 year age . Histologically cytologically document locally advanced metastatic nonsmall cell lung cancer ( inoperable Stage III IV accord 7th TNM Classification Malignant Tumors ) . Experiencing disease progression pemetrexedcontaining firstline chemotherapy regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Initiated secondline treatment Tarceva 4 week prior study entry baseline ( date signature inform consent ) . Prior chemotherapy/targeted therapy disease progression firstline treatment advance nonsmall cell lung cancer ( NSCLC ) setting . Contraindication Tarceva accord Summary Product characteristic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>